Stock Traders Buy High Volume of BioNTech Call Options (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the target of some unusual options trading on Tuesday. Investors purchased 4,599 call options on the company. This represents an increase of 58% compared to the average volume of 2,906 call options.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BNTX shares. HSBC upped their price objective on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. Finally, TD Cowen dropped their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $140.76.

BioNTech Price Performance

Shares of BioNTech stock opened at $122.15 on Thursday. The firm has a market cap of $29.28 billion, a PE ratio of -58.17 and a beta of 0.18. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $113.89 and a 200 day moving average price of $102.93.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same period in the prior year, the business posted $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. Sell-side analysts predict that BioNTech will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of institutional investors have recently made changes to their positions in BNTX. Planning Capital Management Corp increased its stake in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. increased its stake in BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC raised its holdings in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares during the period. Daiwa Securities Group Inc. raised its stake in shares of BioNTech by 430.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after acquiring an additional 1,562 shares during the period. Finally, Caprock Group LLC acquired a new position in shares of BioNTech in the 2nd quarter worth approximately $206,000. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.